Mounjaro
Brand-name tirzepatide FDA-approved for type 2 diabetes; weight-loss use is off-label but common.
Mounjaro arrived in 2022 as tirzepatide for type 2 diabetes, and its glucose results — paired with dramatic weight loss in diabetic patients — made it a blockbuster before Zepbound existed. The two brands contain identical tirzepatide; the label is what differs.
That label drives everything practical: insurance for Mounjaro usually requires a diabetes diagnosis, and prescribing it purely for weight is off-label — legal at a doctor's discretion, but often uncovered. Patients with type 2 diabetes and excess weight are its natural fit; weight-only patients are typically better matched to Zepbound. A prescriber weighing your chart makes that call, which is exactly how our program assigns the brand.
This glossary entry is general information, not medical advice, and is written to be consistent with FDA prescribing information and primary trial publications as of its last review. Always consult a licensed healthcare provider for personal medical decisions.
Questions about Mounjaro? Ask a doctor free.
A licensed doctor can apply this to your health history in a free telehealth consultation — booking takes about two minutes, with programs from $149/month. You're only charged after approval.
Book an Appointment